The downturn at Novo Nordisk A/S could deal a further blow to Danish consumer confidence, with the drugmaker’s slumping ...

Eli Lilly is poised to leapfrog Novo Nordisk and become the dominant player in an anti-obesity drug market that could reach ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

Commentary: Americans generally pay more for brand-name drugs, but also pay significantly less for most generics: over 90% of ...

In what some news reports dubbed " an awkward moment ," CMS Administrator Mehmet Oz, MD, stepped up to the podium in the Oval Office last week to correct President Donald Trump on the status of GLP-1 ...

WW International shares rise nearly 6% after announcing a partnership with Amazon Pharmacy to deliver GLP-1 weight-loss drugs directly to customers.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

President Trump wants to lower GLP-1 prices; Novo Nordisk hires new corporate affairs lead; FDA announces priority drug review candidates.

President Donald Trump on Friday announced a deal with pharmaceutical company Merck and its U.S. subsidiary, EMD Serono, to ...

Doctors called it “huge for patients,” if true. Patients who’ve struggled to afford the pricey medicines shared hope the price could be reached. Stocks of Novo Nordisk and Eli Lilly fell significantly ...

The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat Type 2 diabetes ...